Bayer, a global leader in life sciences with a strong emphasis on healthcare and nutrition, has partnered with the Saudi Heart Association (SHA) in order to strengthen bilateral cooperation to improve cardiac care in Saudi Arabia in alignment with Vision 2030.
The agreement will prioritize early detection of at-risk patients of cardiovascular diseases (CVDs) who exhibit a combination of modifiable risk factors (such as hypertension, smoking, poor diet, physical inactivity, and high cholesterol) and non-modifiable risk factors (such as age, family history, gender, and genetic predisposition).
Under the terms of the partnership, the two entities will seek to advance educational initiatives for healthcare professionals in Saudi Arabia, with a focus on the primary prevention of Atherosclerotic cardiovascular disease (ASCVD).
According to the statement, “Throughout the partnership, emphasis will be placed on delivering educational lectures and hands-on workshops for healthcare professionals, introducing them to the latest diagnostic tools that cost-effectively streamline early CVD detection.”
Additionally, the partnership will promote evidence-based early risk management local guidelines and strategies in clinical practice, aligning resources to achieve superior patient outcomes.
Maged ElShazly, Managing Director of Bayer Saudi Arabia & Country Commercial Lead – Bayer Consumer Health, said that, “This partnership marks a significant step forward in advancing cardiovascular health in the Kingdom. Aligned with Saudi Vision 2030, our goal is to collaborate closely with the SHA to support the government’s efforts in reducing CVD mortality and morbidity, improving heart health, and enhancing the quality of life for individuals at high risk.”
“Additionally, this collaboration with SHA will further propel our efforts to developing and implementing local guidelines for effective CVD management, ensuring long-term impact and sustainability in healthcare practices across the Kingdom,” ElShazly added.
